The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program® (TAP)

How can TAP benefit your company?

Hear what the SVP of Corporate & Business Development of Stemline Therapeutics has to say about TAP and the value created for his company beyond the funding amount. LLS TAP partnered with Stemline in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

European Partners Dream Big, Make Bold Progress 

Leadership provided an overview of LLS TAP’s expansion into Europe and moderated a discussion panel with past and current European TAP portfolio partners who are dreaming big and making bold progress for blood cancer patients. 

A recording of the presentation from Jan. 2023 is to the right.